Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0001415889-23-014366)

Filing Details

Accession Number:: 0001415889-23-014366
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-10-17 19:28:14
Reporting Period:: 2023-10-17

Accepted Time:: 2023-10-17 19:28:14
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1159036	Halozyme Therapeutics Inc.	HALO	Biological Products, (No Disgnostic Substances) (2836)	880488686

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1507174	J. Michael Labarre	C/O Halozyme Therapeutics, Inc. 12390 El Camino Real San Diego CA 92130	Svp, Chief Technical Officer	No	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-10-17	10,000	$19.98	161,911	No	4	M	Direct
Common Stock	Disposition	2023-10-17	10,000	$36.52	151,911	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Option to Purchase Common Stock	Disposition	2023-10-17	10,000	$0.00	10,000	$19.98

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
41,099		2030-02-10	No	4	M	Direct

Footnotes

The option exercise and sale reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on August 30, 2022.
This option was granted on February 10, 2020 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter.